<?xml version="1.0" encoding="UTF-8"?>
<rss xmlns:dc="http://purl.org/dc/elements/1.1/" version="2.0">
<channel>
<title>Volumen 07</title>
<link>http://sedici.unlp.edu.ar:80/handle/10915/125297</link>
<description/>
<pubDate>Thu, 19 Nov 2026 11:35:27 GMT</pubDate>
<dc:date>2026-11-19T11:35:27Z</dc:date>
<item>
<title>Fetoplacental endothelial dysfunction in maternal hypercholesterolemia and obesity in pregnancy</title>
<link>http://sedici.unlp.edu.ar:80/handle/10915/125642</link>
<description>Revision
Physiological Mini Reviews; vol. 7, no. 5
Human fetoplacental vascular function is altered in several pathologies of pregnancy as a result of endothelial dysfunction. Pregnancy is a physiological condition coursing with increased circulating plasma levels of cholesterol in the mother, to respond to the higher demands from the growing fetus. An abnormal increase in maternal plasma cholesterol configures a pathological state referred as maternal supraphysiological hypercholesterolemia (MSPH). In MSPH, L-arginine transport and synthesis of nitric oxide (i.e., L-arginine/NO signalling pathway) as well as arginases/urea cycle in the fetoplacental endothelium are altered. Equally, an increase in the physiological gain of weight in pregnant women could end with obese women at the end of pregnancy leading to a condition referred as obesity in pregnancy (OP). OP seems to be also associated with alterations in the L-arginine/NO signalling pathway in endothelium in animal models; however, nothing is known regarding alterations of the human fetoplacental endothelium in OP. Insulin, adenosine and NO are vasodilators in the fetoplacental vascular bed, and a role for these molecules is proposed in MSPH and OP. Alternatively, involvement of intracellular pH modulation and the potential involvement of adenosine receptors is proposed as phenomena that could improve endothelial dysfunction associated with these diseases of pregnancy.
</description>
<pubDate>Wed, 01 Oct 2014 00:00:00 GMT</pubDate>
<guid isPermaLink="false">http://sedici.unlp.edu.ar:80/handle/10915/125642</guid>
<dc:date>2014-10-01T00:00:00Z</dc:date>
<dc:description>Human fetoplacental vascular function is altered in several pathologies of pregnancy as a result of endothelial dysfunction. Pregnancy is a physiological condition coursing with increased circulating plasma levels of cholesterol in the mother, to respond to the higher demands from the growing fetus. An abnormal increase in maternal plasma cholesterol configures a pathological state referred as maternal supraphysiological hypercholesterolemia (MSPH). In MSPH, L-arginine transport and synthesis of nitric oxide (i.e., L-arginine/NO signalling pathway) as well as arginases/urea cycle in the fetoplacental endothelium are altered. Equally, an increase in the physiological gain of weight in pregnant women could end with obese women at the end of pregnancy leading to a condition referred as obesity in pregnancy (OP). OP seems to be also associated with alterations in the L-arginine/NO signalling pathway in endothelium in animal models; however, nothing is known regarding alterations of the human fetoplacental endothelium in OP. Insulin, adenosine and NO are vasodilators in the fetoplacental vascular bed, and a role for these molecules is proposed in MSPH and OP. Alternatively, involvement of intracellular pH modulation and the potential involvement of adenosine receptors is proposed as phenomena that could improve endothelial dysfunction associated with these diseases of pregnancy.</dc:description>
</item>
<item>
<title>Vitamin D-VDR signaling in bone cells</title>
<link>http://sedici.unlp.edu.ar:80/handle/10915/125640</link>
<description>Revision
Physiological Mini Reviews; vol. 7, no. 6
Vitamin D plays a key role in mineral homeostasis, in which its main biological effect is to maintain adequate serum calcium levels. The systemic deficiency of either 1,25D or its receptor (VDR) is associated with bone alterations such as rickets and osteomalacia. This review summarizes the evidence supporting a direct effect of vit D-VDR on bone cells.&#13;
The presence of vit D-hydroxylases as well as VDR in several cell types, supports an autocrine / paracrine role for vitamin D. Bone-derived cells also express VDR, and thus it is currently hypothesized that 1,25(OH)2 vitamin D (1,25D) directly controls specific aspects of bone and mineral homeostasis. Several forms of vitamin D have been shown to induce specific and direct effects on different cells from bone and cartilage, such as chondrocytes, osteoblasts, osteocytes, osteoclasts and bone marrow stromal cells. Both catabolic and anabolic effects of vitamin D have been demonstrated in bone, mediated by different signal transduction mechanisms. In addition to the classic VDR mediated actions, non-classic and rapid effects of vitamin D have also been demonstrated in bone cells.
</description>
<pubDate>Mon, 01 Dec 2014 00:00:00 GMT</pubDate>
<guid isPermaLink="false">http://sedici.unlp.edu.ar:80/handle/10915/125640</guid>
<dc:date>2014-12-01T00:00:00Z</dc:date>
<dc:description>Vitamin D plays a key role in mineral homeostasis, in which its main biological effect is to maintain adequate serum calcium levels. The systemic deficiency of either 1,25D or its receptor (VDR) is associated with bone alterations such as rickets and osteomalacia. This review summarizes the evidence supporting a direct effect of vit D-VDR on bone cells.&#13;
The presence of vit D-hydroxylases as well as VDR in several cell types, supports an autocrine / paracrine role for vitamin D. Bone-derived cells also express VDR, and thus it is currently hypothesized that 1,25(OH)2 vitamin D (1,25D) directly controls specific aspects of bone and mineral homeostasis. Several forms of vitamin D have been shown to induce specific and direct effects on different cells from bone and cartilage, such as chondrocytes, osteoblasts, osteocytes, osteoclasts and bone marrow stromal cells. Both catabolic and anabolic effects of vitamin D have been demonstrated in bone, mediated by different signal transduction mechanisms. In addition to the classic VDR mediated actions, non-classic and rapid effects of vitamin D have also been demonstrated in bone cells.</dc:description>
</item>
<item>
<title>Deleterious effects of inflammation on parturition and fetal development</title>
<link>http://sedici.unlp.edu.ar:80/handle/10915/125635</link>
<description>Revision
Physiological Mini Reviews; vol. 7, no. 3
Preterm birth is a major determinant of neonatal mortality and morbidity worldwide. One of the main causes of preterm parturition is maternal infection Dissemination of microorganisms from the vagina and cervix via the ascending route is the preponderant way of infection, although microorganisms may also access the amniotic cavity and the fetus via other pathways.&#13;
The pathophysiological processes that are set in motion during maternal infection lead to preterm labor and fetal damage with severe consequences both for the mother as well as the offspring. During inflammation associated to infection, a plethora of pro-inflammatory agents are produced in high levels. Thus, prostaglandins are released simultaneously with nitric oxide and their overproduction promotes uterine contractions contributing to embryonic and fetal expulsion. Oxygen and nitrogen reactive species and proinflammatory cytokines have been associated with preterm birth as well as fetal damage and they might contribute to the high mortality and morbidity associated with preterm labor.&#13;
The study of these pathophysiological processes is necessary to develop better tocolytic agents. Therefore, it is essential to establish good animal models of infection-induced preterm labor that would mimic the human parturition biology.
</description>
<pubDate>Sun, 01 Jun 2014 00:00:00 GMT</pubDate>
<guid isPermaLink="false">http://sedici.unlp.edu.ar:80/handle/10915/125635</guid>
<dc:date>2014-06-01T00:00:00Z</dc:date>
<dc:description>Preterm birth is a major determinant of neonatal mortality and morbidity worldwide. One of the main causes of preterm parturition is maternal infection Dissemination of microorganisms from the vagina and cervix via the ascending route is the preponderant way of infection, although microorganisms may also access the amniotic cavity and the fetus via other pathways.&#13;
The pathophysiological processes that are set in motion during maternal infection lead to preterm labor and fetal damage with severe consequences both for the mother as well as the offspring. During inflammation associated to infection, a plethora of pro-inflammatory agents are produced in high levels. Thus, prostaglandins are released simultaneously with nitric oxide and their overproduction promotes uterine contractions contributing to embryonic and fetal expulsion. Oxygen and nitrogen reactive species and proinflammatory cytokines have been associated with preterm birth as well as fetal damage and they might contribute to the high mortality and morbidity associated with preterm labor.&#13;
The study of these pathophysiological processes is necessary to develop better tocolytic agents. Therefore, it is essential to establish good animal models of infection-induced preterm labor that would mimic the human parturition biology.</dc:description>
</item>
<item>
<title>Hepatic and intestinal biotransformation and transport of xenobiotics during pregnancy and lactation</title>
<link>http://sedici.unlp.edu.ar:80/handle/10915/125634</link>
<description>Revision
Physiological Mini Reviews; vol. 7, no. 2
The liver is the main place for phase II metabolism and transport of xenobiotics mediated by Mrp2, leading to elimination of conjugated metabolites into bile. In the gastrointestinal tract, phase II enzymes and Mrp2 are preferentially localized in the proximal region of the small intestine, particularly at the tip of the villus. In pregnant rats, conjugating enzymes (e.g. UGT and GST) and Mrp2-mediated transport of xenobiotics are decreased when compared to normal females, whereas these systems are preserved in small intestine, suggesting a complementary role for this tissue. After delivery, these same enzymes increase their expression and activity, being maximal during the last week of lactation.&#13;
Mrp2 protein in liver also recovers and reaches the control level by the end of the lactation period. Post-partum rats exhibit a significant increase in development of the digestive tract in association with induction of phase II enzymes and Mrp2 expression and activity.&#13;
Although the factors involved in regulation of protein expression may not be the same for conjugating enzymes and Mrp2 in the different experimental situations or tissues studied, their common localization and co-regulation provide evidence that they may work in cooperation. This is not surprising if we consider that most of the substrates for MRPs are the products that result from phase II reactions. Here, we provide a brief description of regulation of major phase II enzymes and Mrp2 during pregnancy and lactation, as particularly seen in the rat.
</description>
<pubDate>Tue, 01 Apr 2014 00:00:00 GMT</pubDate>
<guid isPermaLink="false">http://sedici.unlp.edu.ar:80/handle/10915/125634</guid>
<dc:date>2014-04-01T00:00:00Z</dc:date>
<dc:description>The liver is the main place for phase II metabolism and transport of xenobiotics mediated by Mrp2, leading to elimination of conjugated metabolites into bile. In the gastrointestinal tract, phase II enzymes and Mrp2 are preferentially localized in the proximal region of the small intestine, particularly at the tip of the villus. In pregnant rats, conjugating enzymes (e.g. UGT and GST) and Mrp2-mediated transport of xenobiotics are decreased when compared to normal females, whereas these systems are preserved in small intestine, suggesting a complementary role for this tissue. After delivery, these same enzymes increase their expression and activity, being maximal during the last week of lactation.&#13;
Mrp2 protein in liver also recovers and reaches the control level by the end of the lactation period. Post-partum rats exhibit a significant increase in development of the digestive tract in association with induction of phase II enzymes and Mrp2 expression and activity.&#13;
Although the factors involved in regulation of protein expression may not be the same for conjugating enzymes and Mrp2 in the different experimental situations or tissues studied, their common localization and co-regulation provide evidence that they may work in cooperation. This is not surprising if we consider that most of the substrates for MRPs are the products that result from phase II reactions. Here, we provide a brief description of regulation of major phase II enzymes and Mrp2 during pregnancy and lactation, as particularly seen in the rat.</dc:description>
</item>
<item>
<title>The role of the neuregulin-1/erbb signaling pathway in cardiac morphogenesis and&#13;
remodeling</title>
<link>http://sedici.unlp.edu.ar:80/handle/10915/125631</link>
<description>Revision
Physiological Mini Reviews; vol. 7, no. 1
Neuregulin-1 (NRG1) signaling through tyrosine kinase receptors erbB2 and erbB4 was revealed essential for cardiac development as mouse mutated in the Nrg1 or either cognate receptors Erbb2 or Erbb4 genes lack the formation of trabeculae at the ventricular wall.&#13;
Indeed, the injection of the NRG1 active peptide in developing embryos induced trabeculation of the ventricular free wall. The components of the NRG1 pathway have been identified and the cardiac activities are being progressively characterized. An acquired form of dilated cardiomyopathy was evidenced in a subpopulation of breast tumor patients undergoing a combined treatment with antibodies against erbB2 and chemotherapy. In this regard, the cardiomyocyte-specific gene deletion of either erbb2 or erbb4 leads to ventricular dilation in adult mice, providing an experimental model system to examine the NRG1-mediated activities. We reviewed the evidence on the growing field of research for NRG1 signaling in both cardiac morphogenesis and in the postnatal myocardial remodeling.
</description>
<pubDate>Sat, 01 Feb 2014 00:00:00 GMT</pubDate>
<guid isPermaLink="false">http://sedici.unlp.edu.ar:80/handle/10915/125631</guid>
<dc:date>2014-02-01T00:00:00Z</dc:date>
<dc:description>Neuregulin-1 (NRG1) signaling through tyrosine kinase receptors erbB2 and erbB4 was revealed essential for cardiac development as mouse mutated in the Nrg1 or either cognate receptors Erbb2 or Erbb4 genes lack the formation of trabeculae at the ventricular wall.&#13;
Indeed, the injection of the NRG1 active peptide in developing embryos induced trabeculation of the ventricular free wall. The components of the NRG1 pathway have been identified and the cardiac activities are being progressively characterized. An acquired form of dilated cardiomyopathy was evidenced in a subpopulation of breast tumor patients undergoing a combined treatment with antibodies against erbB2 and chemotherapy. In this regard, the cardiomyocyte-specific gene deletion of either erbb2 or erbb4 leads to ventricular dilation in adult mice, providing an experimental model system to examine the NRG1-mediated activities. We reviewed the evidence on the growing field of research for NRG1 signaling in both cardiac morphogenesis and in the postnatal myocardial remodeling.</dc:description>
</item>
<item>
<title>Current strategies to prevent ishcemia reperfusion injury in organ transplantation</title>
<link>http://sedici.unlp.edu.ar:80/handle/10915/102619</link>
<description>Revision
Physiological Mini Reviews; vol. 7, no. 4
Solid organ transplantation is inherently associated to ischemia reperfusion injury (IRI) since the operative procedure always impliesthe harvesting, preservation and implantation of the organ,whichresult in several hours of ischemia followed by reperfusion. Several strategies have been proposed to mitigate IRI in organ transplantation.However, most of them are in experimental phases and currently few are implemented in the clinical field. These strategies can be applied in 3 different stages of the transplantation procedure: on the organ donor, known as donor pre-treatment; during preservation, when ischemic organ is waiting to be implanted in the recipient or on the transplant recipient. In the present review, we will discuss the different approaches to control IRI damage in solid organ transplantation and the rationale behind them.
</description>
<pubDate>Tue, 01 Jul 2014 00:00:00 GMT</pubDate>
<guid isPermaLink="false">http://sedici.unlp.edu.ar:80/handle/10915/102619</guid>
<dc:date>2014-07-01T00:00:00Z</dc:date>
<dc:description>Solid organ transplantation is inherently associated to ischemia reperfusion injury (IRI) since the operative procedure always impliesthe harvesting, preservation and implantation of the organ,whichresult in several hours of ischemia followed by reperfusion. Several strategies have been proposed to mitigate IRI in organ transplantation.However, most of them are in experimental phases and currently few are implemented in the clinical field. These strategies can be applied in 3 different stages of the transplantation procedure: on the organ donor, known as donor pre-treatment; during preservation, when ischemic organ is waiting to be implanted in the recipient or on the transplant recipient. In the present review, we will discuss the different approaches to control IRI damage in solid organ transplantation and the rationale behind them.</dc:description>
</item>
</channel>
</rss>
